Skip to content
value.today

Acer Therapeutics Inc.

🇺🇸 Cambridge, Massachusetts, USAPharmaceuticalsFounded 2013
Total raised
$24 M
2 rounds on record
Latest round
$16 M
Sep 2017
First round on record
Apr 2016
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Acer Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2017$16 MNo. 2$10 to $50 million

Acer Therapeutics Inc.: Raise no. 2, Sep 2017

Investors in this round

10 investors had bought by the notice of Oct 4, 2017: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$16 M of $16 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,097,026
Finders' fees
$67,495
Paid to its own people
$948,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and finders' fees and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher Schelling · Executive Officer, Director
  • Harry S. Palmin · Executive Officer
  • Robert S. Steiner · Executive Officer
  • Hubert Birner · Director
  • John Dunn · Director
  • Luc Marengere · Director
  • Stephen Aselage · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Piper Jaffray & Co. (CRD 665) · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “The sales commission and finders' fees reflect amounts described in an invoice provided by Piper Jaffray & Co. The total amount payable remains in dispute.”
  • On the use of proceeds: “The Issuer expects to use approximately $948,000 of the proceeds for salary and other compensation to the Issuer's executive officers and directors.”

Signed by Harry S. Palmin, Chief Financial Officer. Source: SEC Form D, newest notice filed Oct 4, 2017. Read the notice at the SEC.

equitySEC
Apr 2016$8 MNo. 1$2 to $10 million

Acer Therapeutics Inc.: Raise no. 1, Apr 2016

Investors in this round

6 investors had bought by the notice of May 6, 2016: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$740,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher Schelling · Executive Officer, Director, Promoter
  • Cynthia Lavoie · Director
  • John Dunn · Director
  • Luc Marengere · Director
  • Stephen Aselage · Director
  • Harry S. Palmin · Promoter

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The exact Total Offering Amount and Total Amount Sold are $8,149,999.20”
  • On the use of proceeds: “The Issuer expects to use approximately $740,000 of the proceeds for salary and other compensation to the Issuer's executive officers, directors and promoters during the 2016 fiscal year.”

Signed by Christopher Schelling, President & CEO. Source: SEC Form D and 1 amendment, newest notice filed May 6, 2016. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Acer Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2017).

    SEC Form D · Oct 2017

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Oct 2017

That is all the official record says: Acer Therapeutics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Acer Therapeutics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 10 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Acer Therapeutics Inc.
NameRoleNamed in
Christopher SchellingExecutive officerOct 2017
Harry S. PalminExecutive officerOct 2017
Robert S. SteinerExecutive officerOct 2017
Christopher SchellingDirectorOct 2017
Hubert BirnerDirectorOct 2017
John DunnDirectorOct 2017
Luc MarengereDirectorOct 2017
Stephen AselageDirectorOct 2017
Cynthia LavoieDirectorMay 2016
Christopher SchellingPromoterMay 2016
Harry S. PalminPromoterMay 2016